The trial accomplished equally its Main endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and exceptional advancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH when compared to placebo.oneSemaglutide is a